ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

ACOS Survey To Assess Tumor Boards’ Impact On Patient Care

January 24, 1986

Advocacy Group Urges FDA to Sift Through Avastin Glioblastoma Data—Agency Accepts

June 14, 2013

Fruit, Candy Flavored Cigarettes Banned In U.S.; FDA To Examine Menthol Flavored Tobacco

September 25, 2009

NCI program announcement available, contract awards listed.

November 14, 2003

Proposed Deal Could Resolve Key Disputes At NSABP, Pitt

January 13, 1995

Budget Would Support 1,211 More Grants

February 7, 2003